Human metapneumovirus

Inhalon Biopharma Expands Therapeutic Horizons with Licensing of hMPV Antibodies from the University of Georgia

Retrieved on: 
Wednesday, November 1, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Sneeze, RSV, Urinary tract infection, Vaccine, Bronchitis, Virus, Pneumonia, Fever, University, Cough, Human, Disease, COVID-19, Antibody, Nasal congestion, Human metapneumovirus, ARI, Infection, Immunology, Patient, Associate

Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced a new agreement with the University of Georgia to license a panel of Human Metapneumovirus (hMPV) antibodies.

Key Points: 
  • Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced a new agreement with the University of Georgia to license a panel of Human Metapneumovirus (hMPV) antibodies.
  • With this license, Inhalon Biopharma plans to select antibody candidates to advance into clinical development for the treatment of hMPV.
  • “This agreement allows us to continue building a robust pipeline of potential treatments for acute respiratory infections on our innovative platform,” said John Whelan, president and chief executive officer, Inhalon Biopharma.
  • I am hopeful that our work can one day ease the burden of disease for individuals affected by hMPV," said Jarrod Mousa, Ph.D., Associate Professor at the Center for Vaccines and Immunology, Department of Infectious Diseases at the University of Georgia whose lab developed the antibodies.

Meissa Appoints Robert Walker, M.D., Chief Medical Officer

Retrieved on: 
Tuesday, August 3, 2021
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Pneumoviridae, Medical specialties, Vaccination, Human metapneumovirus, Respiratory syncytial virus, Metapneumovirus, Vaccine, Microbiology, Clinical medicine

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the appointment of Robert Walker, M.D., as Chief Medical Officer.

Key Points: 
  • Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the appointment of Robert Walker, M.D., as Chief Medical Officer.
  • Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and at-risk, older adults from RSV.
  • Prior to joining Meissa, Dr. Walker was Chief Medical Officer and Director of the Division of Clinical Development at the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Department of Health and Human Services (HHS).
  • Meissa is advancing live attenuated vaccine candidates against respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).

Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

Retrieved on: 
Wednesday, June 30, 2021
FDA, Other Health, Women, Seniors, Infectious diseases, Hospitals, Parenting, MEN, Children, Baby, Maternity, Clinical trials, Biotechnology, Science, Other Science, Consumer, Health, Medical specialties, Vaccination, Virology, Medicine, Clinical medicine, Vaccines, Atypical pneumonias, Respiratory syncytial virus vaccine, Human metapneumovirus, Respiratory syncytial virus, Vaccine, Attenuated vaccine, MV-012-968, AttenuBlockTM Platform, Meissa Vaccines, MV-012-968, ATTENUBLOCKTM PLATFORM, MEISSA VACCINES

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the first seronegative participants have received MV-012-968, Meissas intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.

Key Points: 
  • Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the first seronegative participants have received MV-012-968, Meissas intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.
  • Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and at-risk, older adults from respiratory syncytial virus (RSV).
  • We believe that our intranasal live attenuated RSV vaccine candidate, developed on Meissas AttenuBlockTM vaccine platform, offers the potential to finally immunize against RSV, which has evaded other vaccine technologies for more than 60 years, said Martin Moore, Ph.D., CEO and cofounder of Meissa Vaccines.
  • Meissa is advancing live attenuated vaccine candidates against respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).

Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate

Retrieved on: 
Tuesday, June 8, 2021
Health, Infectious diseases, General Health, Clinical trials, Research, Science, Biotechnology, Clinical trials, COVID-19 vaccines, RNA vaccines, Medicine, Health sciences, Articles, COVID-19 vaccine, Medical research, Human metapneumovirus, CoVLP, H5N1 clinical trials, Virus-Like Particles (VLP) Vaccines, IVX-411, COVID-19 VLP Vaccine Candidate, Icosavax, VIRUS-LIKE PARTICLES (VLP) VACCINES, IVX-411, COVID-19 VLP VACCINE CANDIDATE, ICOSAVAX

We are pleased to be working with Seqirus to evaluate MF59 in combination with IVX-411, our COVID-19 VLP vaccine candidate.

Key Points: 
  • We are pleased to be working with Seqirus to evaluate MF59 in combination with IVX-411, our COVID-19 VLP vaccine candidate.
  • The Phase 1/2 clinical trial is a randomized, observer-blinded, placebo-controlled trial designed to evaluate the safety and immunogenicity of adjuvanted and unadjuvanted IVX-411.
  • The Phase 2 part of the trial will enroll SARS-CoV-2 seropositive adults who have completed a vaccine regimen using a licensed COVID-19 vaccine.
  • Icosavax is advancing VLP vaccine candidates against respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2 (COVID-19).

Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver

Retrieved on: 
Thursday, June 3, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Chemical compounds, Organic compounds, Chemistry, Carbamates, Healthcare-associated infections, Glecaprevir/pibrentasvir, Infectious causes of cancer, Glecaprevir, Hepatitis C, AbbVie, Human metapneumovirus, Pibrentasvir

Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).

Key Points: 
  • Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
  • Enanta is also conducting research in SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir).

Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Tuesday, May 11, 2021
Research, Infectious diseases, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Chemical compounds, Organic compounds, Chemistry, Carbamates, Healthcare-associated infections, Pneumoviridae, Glecaprevir/pibrentasvir, Glecaprevir, Hepatitis C, Pibrentasvir, Human metapneumovirus, AbbVie

Enanta\xe2\x80\x99s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).

Key Points: 
  • Enanta\xe2\x80\x99s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
  • Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).\nEnanta\xe2\x80\x99s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET\xc2\xae (U.S.) and MAVIRET\xc2\xae (ex-U.S.) (glecaprevir/pibrentasvir).
  • Please visit www.enanta.com for more information.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005247/en/\n'

Meissa Vaccines Appoints Dr. Michael Watson to Board of Directors

Retrieved on: 
Tuesday, April 13, 2021
Health, Infectious diseases, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Pneumoviridae, Medical specialties, Human metapneumovirus, Vaccination, Respiratory syncytial virus, Syncytial virus, Attenuated vaccine, Microbiology, Metapneumovirus, Biology

b'Meissa Vaccines (\xe2\x80\x9cMeissa\xe2\x80\x9d), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the appointment of Dr. Michael Watson to the Company\xe2\x80\x99s Board of Directors.

Key Points: 
  • b'Meissa Vaccines (\xe2\x80\x9cMeissa\xe2\x80\x9d), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the appointment of Dr. Michael Watson to the Company\xe2\x80\x99s Board of Directors.
  • Currently, he is the cofounder and CEO of MEVOX, CEO of VaxEquity, and Board member of the Foundation for Innovative New Diagnostics (FIND).
  • Meissa is advancing live attenuated vaccine candidates against respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).
  • Meissa is headquartered in Redwood City, Calif. For more information, please visit www.meissavaccines.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005098/en/\n'

Meissa Announces IND Clearance for Phase 1 Study of Intranasal Live Attenuated Vaccine Candidate for COVID-19

Retrieved on: 
Tuesday, March 16, 2021
FDA, Pharmaceutical, General Health, Women, Infectious diseases, Seniors, Hospitals, MEN, Clinical trials, Science, Biotechnology, Consumer, Other Science, Health, Research, Vaccination, Medical specialties, Virology, Medicine, Health sciences, Medical research, COVID-19 vaccine, Human metapneumovirus, Vaccine, Attenuated vaccine, Clinical trials, Novavax, MV-014-212: A Unique Intranasal Live Attenuated Vaccine Candidate for COVID-19, Meissa Vaccines

Furthermore, a single intranasal dose of Meissas COVID-19 vaccine candidate, MV-014-212, may be sufficient to generate durable immunity against SARS-CoV-2 and its variants.

Key Points: 
  • Furthermore, a single intranasal dose of Meissas COVID-19 vaccine candidate, MV-014-212, may be sufficient to generate durable immunity against SARS-CoV-2 and its variants.
  • We think Meissas intranasal COVID-19 vaccine candidate can be a globally accessible, end-game vaccine.
  • The AttenuBlock platform has also produced the companys RSV live attenuated vaccine candidate, MV-012-968 , which is in Phase 2 clinical studies.
  • Meissa is advancing live attenuated vaccine candidates against respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).

Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, March 2, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Pneumoviridae, Healthcare-associated infections, Health, Medical specialties, Infectious causes of cancer, Human metapneumovirus, Metapneumovirus, Hepatitis C, Hepatitis

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences:

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences:
    H.C. Wainwright & Co.
  • A replay of each webcast will be available following the presentations and will be archived for approximately 90 days.
  • Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.

Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

Retrieved on: 
Thursday, January 21, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Genetics, Clinical trials, Pneumoviridae, Medical specialties, Atypical pneumonias, Paramyxoviridae, Human metapneumovirus, Respiratory syncytial virus, Clinical medicine, Microbiology, Syncytial virus, RSV, Attenuated vaccine, Orthopneumovirus

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the first adult participants have been dosed in a Phase 2 study of MV-012-968, the companys intranasal live attenuated vaccine candidate against respiratory syncytial virus (RSV).

Key Points: 
  • Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the first adult participants have been dosed in a Phase 2 study of MV-012-968, the companys intranasal live attenuated vaccine candidate against respiratory syncytial virus (RSV).
  • Meissa is developing MV-012-968, an intranasal (needle-free), live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV.
  • Meissa plans to initiate a Phase 1c study in sero-negative infants in the first half of this year.
  • Meissa is advancing live attenuated vaccine candidates against life threatening respiratory viruses, including respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).